S-1 Prolongs Survival Compared With Taxanes for Treatment of Metastatic Breast Cancer

Share this content:
A new study provided firm evidence for the benefit of S-1 in treatment of patients with metastatic breast cancer.
A new study provided firm evidence for the benefit of S-1 in treatment of patients with metastatic breast cancer.

A new study from Japan provided firm evidence for the benefit of S-1 in treatment of patients with metastatic breast cancer (mBC).

The results, published online in Lancet Oncology by lead author Tsutomu Takashima and the SELECT BC group, show that, as first-line chemotherapy for mBC, S-1 produced similar efficacy as taxane therapy, with better health-related quality of life due to a different adverse-effect profile.1

The study was designed to demonstrate that S-1 (a combination oral drug containing fluorouracil, tegafur, gimeracil, and oteracil) was non-inferior to taxane therapy (a standard therapy for women with estrogen-receptor negative or endocrine-resistant mBC), with a primary endpoint of overall survival (OS).

Investigators from the multicenter study enrolled women aged 20 to 75 years (n = 592), with human epidermal growth factor receptor (HER)2-negative, endocrine therapy-resistant mBC who had not previously received chemotherapy for their metastatic disease. Women with brain metastases were excluded.

Researchers randomly assigned patients to receive a standard taxane regimen (docetaxel or paclitaxel) or S-1 (twice daily x 28 days, followed by 14-day rest period). Treatment continued for 6 courses or until tumor progression or unacceptable toxicity occurred. The median age of women in the study was approximately 59 years; median follow-up was 34.6 months.

Median OS was similar between S-1 (35.0 months) and taxane therapy (37.2 months). Statistical analysis showed that S-1 was non-inferior to taxane (P for non-inferiority = .015). The median time to treatment failure was 8.0 months with S-1 and 8.9 months with taxanes. Median progression-free survival was 9.6 vs 11 months, respectively. The researchers also assessed safety and tolerability.

RELATED: Declines in Top1-positive Circulating Tumor Cells Associated With Prolonged Survival After Etirinotecan Pegol

The most common grade ≥ 3 events with S-1 or taxanes, respectively, were neutropenia (7% vs 3%), fatigue (3% vs 4%), and edema (< 1% vs 4%). Side effects commonly reported by patients as problematic—hair loss, edema, and peripheral neuropathies—were rare with S-1 and occurred at significantly lower rates than with taxanes.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs